Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases

Montserrat Feijóo, Isaac Túnez, Inmaculada Tasset, Pedro Montilla, Verónica Pérez-Guijo, Elisa Muñoz-Gomariz, Adela Ruiz, Ruxandra Schiotis, Eduardo Collantes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The present study evaluated the effect of infliximab on the myeloperoxidase (MPO) concentration in chronic inflammatory joint disease. Eighteen patients were divided into active and inactive groups. Erythrocyte sedimentation rate, C-reactive protein, white blood cell counts, MPO concentration, and biomarkers of oxidative stress were measured before and after the infusion of infliximab. Patients with active disease showed increases in concentrations of MPO and biomarkers of oxidation, but decreases in antioxidant parameters. After infliximab treatment, both inflammatory parameters and MPO concentrations were normalized. In conclusion: (1) the MPO concentration is related to inflammatory activity and could play an important role in the maintenance and outbreak of oxidative stress present in these diseases, and (2) infliximab inhibits MPO concentration.

Original languageEnglish (US)
Pages (from-to)211-216
Number of pages6
JournalPharmacology
Volume83
Issue number4
DOIs
StatePublished - Apr 2009
Externally publishedYes

Fingerprint

Joint Diseases
Peroxidase
Oxidative Stress
Biomarkers
Blood Sedimentation
Leukocyte Count
C-Reactive Protein
Disease Outbreaks
Infliximab
Antioxidants
Maintenance

Keywords

  • Ankylosing spondylitis
  • Chronic inflammatory joint disease
  • Infliximab
  • Myeloperoxidase
  • Oxidative stress
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Feijóo, M., Túnez, I., Tasset, I., Montilla, P., Pérez-Guijo, V., Muñoz-Gomariz, E., ... Collantes, E. (2009). Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases. Pharmacology, 83(4), 211-216. https://doi.org/10.1159/000200022

Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases. / Feijóo, Montserrat; Túnez, Isaac; Tasset, Inmaculada; Montilla, Pedro; Pérez-Guijo, Verónica; Muñoz-Gomariz, Elisa; Ruiz, Adela; Schiotis, Ruxandra; Collantes, Eduardo.

In: Pharmacology, Vol. 83, No. 4, 04.2009, p. 211-216.

Research output: Contribution to journalArticle

Feijóo, M, Túnez, I, Tasset, I, Montilla, P, Pérez-Guijo, V, Muñoz-Gomariz, E, Ruiz, A, Schiotis, R & Collantes, E 2009, 'Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases', Pharmacology, vol. 83, no. 4, pp. 211-216. https://doi.org/10.1159/000200022
Feijóo M, Túnez I, Tasset I, Montilla P, Pérez-Guijo V, Muñoz-Gomariz E et al. Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases. Pharmacology. 2009 Apr;83(4):211-216. https://doi.org/10.1159/000200022
Feijóo, Montserrat ; Túnez, Isaac ; Tasset, Inmaculada ; Montilla, Pedro ; Pérez-Guijo, Verónica ; Muñoz-Gomariz, Elisa ; Ruiz, Adela ; Schiotis, Ruxandra ; Collantes, Eduardo. / Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases. In: Pharmacology. 2009 ; Vol. 83, No. 4. pp. 211-216.
@article{c3c933f50f4e4d98b4b526b12c473533,
title = "Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases",
abstract = "The present study evaluated the effect of infliximab on the myeloperoxidase (MPO) concentration in chronic inflammatory joint disease. Eighteen patients were divided into active and inactive groups. Erythrocyte sedimentation rate, C-reactive protein, white blood cell counts, MPO concentration, and biomarkers of oxidative stress were measured before and after the infusion of infliximab. Patients with active disease showed increases in concentrations of MPO and biomarkers of oxidation, but decreases in antioxidant parameters. After infliximab treatment, both inflammatory parameters and MPO concentrations were normalized. In conclusion: (1) the MPO concentration is related to inflammatory activity and could play an important role in the maintenance and outbreak of oxidative stress present in these diseases, and (2) infliximab inhibits MPO concentration.",
keywords = "Ankylosing spondylitis, Chronic inflammatory joint disease, Infliximab, Myeloperoxidase, Oxidative stress, Rheumatoid arthritis",
author = "Montserrat Feij{\'o}o and Isaac T{\'u}nez and Inmaculada Tasset and Pedro Montilla and Ver{\'o}nica P{\'e}rez-Guijo and Elisa Mu{\~n}oz-Gomariz and Adela Ruiz and Ruxandra Schiotis and Eduardo Collantes",
year = "2009",
month = "4",
doi = "10.1159/000200022",
language = "English (US)",
volume = "83",
pages = "211--216",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases

AU - Feijóo, Montserrat

AU - Túnez, Isaac

AU - Tasset, Inmaculada

AU - Montilla, Pedro

AU - Pérez-Guijo, Verónica

AU - Muñoz-Gomariz, Elisa

AU - Ruiz, Adela

AU - Schiotis, Ruxandra

AU - Collantes, Eduardo

PY - 2009/4

Y1 - 2009/4

N2 - The present study evaluated the effect of infliximab on the myeloperoxidase (MPO) concentration in chronic inflammatory joint disease. Eighteen patients were divided into active and inactive groups. Erythrocyte sedimentation rate, C-reactive protein, white blood cell counts, MPO concentration, and biomarkers of oxidative stress were measured before and after the infusion of infliximab. Patients with active disease showed increases in concentrations of MPO and biomarkers of oxidation, but decreases in antioxidant parameters. After infliximab treatment, both inflammatory parameters and MPO concentrations were normalized. In conclusion: (1) the MPO concentration is related to inflammatory activity and could play an important role in the maintenance and outbreak of oxidative stress present in these diseases, and (2) infliximab inhibits MPO concentration.

AB - The present study evaluated the effect of infliximab on the myeloperoxidase (MPO) concentration in chronic inflammatory joint disease. Eighteen patients were divided into active and inactive groups. Erythrocyte sedimentation rate, C-reactive protein, white blood cell counts, MPO concentration, and biomarkers of oxidative stress were measured before and after the infusion of infliximab. Patients with active disease showed increases in concentrations of MPO and biomarkers of oxidation, but decreases in antioxidant parameters. After infliximab treatment, both inflammatory parameters and MPO concentrations were normalized. In conclusion: (1) the MPO concentration is related to inflammatory activity and could play an important role in the maintenance and outbreak of oxidative stress present in these diseases, and (2) infliximab inhibits MPO concentration.

KW - Ankylosing spondylitis

KW - Chronic inflammatory joint disease

KW - Infliximab

KW - Myeloperoxidase

KW - Oxidative stress

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=59549096837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59549096837&partnerID=8YFLogxK

U2 - 10.1159/000200022

DO - 10.1159/000200022

M3 - Article

VL - 83

SP - 211

EP - 216

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

IS - 4

ER -